Abstract
Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.
Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
Keywords: ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), TNF-inhibitors, tocilizumab.
Current Pharmaceutical Biotechnology
Title:Biologics in Inflammatory Immune-mediated Systemic Diseases
Volume: 18 Issue: 12
Author(s): Gianluca Moroncini*, Giovanni Calogera, Devis Benfaremo and Armando Gabrielli
Affiliation:
- Clinica Medica, Dipartimento di Scienze Cliniche e Molecolari, Universita Politecnica delle Marche, Ancona,Italy
Keywords: ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), TNF-inhibitors, tocilizumab.
Abstract: Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.
Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.
Export Options
About this article
Cite this article as:
Moroncini Gianluca*, Calogera Giovanni , Benfaremo Devis and Gabrielli Armando , Biologics in Inflammatory Immune-mediated Systemic Diseases, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666171226152448
DOI https://dx.doi.org/10.2174/1389201019666171226152448 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Design and Delivery of Therapeutic siRNAs: Application to MERS-Coronavirus
Current Pharmaceutical Design Inhibitors of Membrane Receptors Involved with Leukocyte Extravasation
Mini-Reviews in Medicinal Chemistry The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Statins Therapy for Connective Tissue Diseases: New Therapeutic Opportunities
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Involvement of IL-1R/TLR Signalling in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Molecular Medicine Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Celastrol Inhibits Inflammatory Stimuli-Induced Neutrophil Extracellular Trap Formation
Current Molecular Medicine Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design No Zinc Deficiency But a Putative Immunosuppressive Role for Labile Zn in Patients with Systemic Autoimmune Disease
Current Rheumatology Reviews Editorial: Current Vision of Systemic Autoimmune Diseases - From Diagnosis to Management
Endocrine, Metabolic & Immune Disorders - Drug Targets The Expanding Role of TNF-Receptor Super Family Member CD40 (tnfrsf5) in Autoimmune Disease: Focus on Th40 Cells
Current Immunology Reviews (Discontinued) Food Ingredients and Lipid Mediators
Current Nutrition & Food Science Dendritic Cell Homeostasis in the Regulation of Self-Reactivity
Current Pharmaceutical Design